Drug intelligence / Profile preview

mylabris

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

**Mylabris** is a traditional Chinese medicine consisting of the dried bodies of blister beetles, primarily from the species Mylabris phalerata and Mylabris cichorii. The main bioactive component of mylabris is cantharidin, a terpenoid lactone. Mylabris and its preparations have a long history of use in traditional Chinese medicine, primarily for their antitumor properties and ability to stimulate bone marrow. Modern research demonstrates that mylabris exhibits anti-cancer activities, particularly against leukemia and other cancers (e.g., liver, pancreatic, and bladder cancers), and contains several active compounds, such as cantharidin, linoleic acid, and oleic acid. Mechanistically, mylabris and its constituents exert pharmacological effects mainly by acting on the p53 signaling pathway, targeting the TP53 and PTEN genes, leading to DNA damage, cell cycle arrest, and induction of apoptosis in tumor cells. Cantharidin, the principal medicinal component, is a potent inhibitor of protein phosphatases 1 and 2A (PP1, PP2A), which affects cell cycle regulation and promotes tumor cell death. Major adverse effects include irritant toxicity, particularly to the urinary tract[1][2][4].

Other names
mylabrisChinese blister beetleMylabris phalerataMylabris cichorii
02

Targets

PTEN (Phosphatase and tensin homolog deleted on chromosome ten)PP1 (Protein phosphatase 1)TP53 (Cellular Tumor Antigen p53 R175H)PP2A (Protein phosphatase 2A)

Beyond the preview

Go deeper on mylabris.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mylabris.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call